Volume 4, Issue 3 (1-2013)                   Caspian J Intern Med 2013, 4(3): 727-730 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mahmoodi Nesheli H, Hadizadeh A, Bijani A. Evaluation of inhibitor antibodies in haemophilia A population. Caspian J Intern Med 2013; 4 (3) :727-730
URL: http://caspjim.com/article-1-212-en.html
Abstract:   (7829 Views)
Background: Inhibitory antibody to exogenous Factor VIII (FVIII) is a major complication of hemophilia treatment. This study was conducted to determine the prevalence of inhibitor antibody directed against FVIII.
Methods: From May 2010 to May 2011, 52 patients with severe hemophilia A admitted in Amirkola Children’s Hospital were evaluated. Those who had abnormal mixing study, antibody against FVIII were measured. Data were collected and analyzed.
Results: The age range of the patients was 4-60 years. The inhibitor antibody was seen in 9 (17.3%) patients. The mean age of patients with inhibitor at the time of diagnosis was 10.22 years (ranged 4-31 years). Old patients had more hemarthrosis than young patients. The mean level of inhibitor antibody was 8.47 Bethesda (ranged 2.3-29). Six patients had inhibitor antibody level ?5 Bethesda unit and three patients had inhibitor antibody level<5 Bethesda unit.
Conclusion: This study showed that the prevalence of inhibitor antibody in young patients is more than the old patients.
Full-Text [PDF 92 kb]   (1924 Downloads)    
Type of Study: Original Article | Subject: Infectious Diseases
Received: 2014/01/17 | Accepted: 2014/01/17 | Published: 2014/01/17

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Caspian Journal of Internal Medicine

Designed & Developed by: Yektaweb